Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Eyenovia (EYEN – Research Report) and Inhibikase Therapeutics (IKT – Research Report).
Irhythm Technologies (IRTC)
In a report released today, Eugene Mannheimer from Colliers Securities maintained a Hold rating on Irhythm Technologies. The company’s shares closed last Wednesday at $53.90, close to its 52-week low of $53.56.
According to TipRanks.com, Mannheimer is a 4-star analyst with an average return of 18.5% and a 56.3% success rate. Mannheimer covers the Technology sector, focusing on stocks such as Computer Programs and Systems, NextGen Healthcare, and Castlight Health.
The word on The Street in general, suggests a Hold analyst consensus rating for Irhythm Technologies with a $81.00 average price target, which is a 37.3% upside from current levels. In a report issued on July 13, BTIG also downgraded the stock to Hold.
Northland Securities analyst Tim Chiang reiterated a Buy rating on Eyenovia yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $4.71.
According to TipRanks.com, Chiang is a 1-star analyst with an average return of -1.8% and a 50.0% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Protagonist Therapeutics, and Verrica Pharmaceuticals.
Currently, the analyst consensus on Eyenovia is a Moderate Buy with an average price target of $12.00.
Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics received a Buy rating and a $12.00 price target from JonesTrading analyst Soumit Roy today. The company’s shares closed last Wednesday at $2.44, close to its 52-week low of $2.38.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 35.2% and a 41.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $12.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.